Silence Therapeutics is no longer a leftover lipoprotein partner-search sitting on a Phase-three-ready cardiovascular file. The August SANRECO readout converted the London siRNA shop into a wholly owned rare-disease story with a registrational path in polycythemia vera. Divesiran produced a controlled response rate that left little ambiguity about whether silencing TMPRSS6 works in phlebotomy-dependent patients. Management called the print the best-case outcome from the Phase one follow-through. The equity debate now sits on whether that signal survives a larger and longer trial, and whether the just-closed follow-on actually funds that trial without another trip to the market.
The financing is the other half of the August event. Silence closed an upsized depositary offering with the overallotment taken in full. Gross proceeds reached $201 million. That cash arrives after a year in which collaboration revenue essentially vanished once AstraZeneca handed back the ANGPTL3 program and Hansoh stepped away from earlier targets. Pre-deal cash sat at $72 million at mid-year. The raise therefore does two jobs at once. It funds a Phase three start planned for the first half of next year, and it prices a large slug of new paper into a book that had already been waiting on the readout. Dilution is the explicit cost of converting a binary data event into a funded development plan.
The controlled trial enrolled forty-eight phlebotomy-dependent patients and hit its primary endpoint on both dosing intervals. Responders needed no phlebotomy and held hematocrit below forty-five percent in the back half of the blinded window. Quarterly dosing still cleared that bar at a high rate, which is why the planned confirmatory study uses the less frequent schedule. The counterargument is sample size and competitive context. A hepcidin-pathway peptide is already further along in the same disease, and a forty-eight-patient study cannot settle uncommon safety or commercial uptake. The open question is whether quarterly siRNA still earns a registrational and commercial role once a larger trial and a competing standard are both in view.